Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimodipine - Grace Therapeutics

Next Previous
Search
Drug Profile

Nimodipine - Grace Therapeutics

Alternative Names: GTX 104; Nimodipine intravenous - Grace Therapeutics

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grace Therapeutics
  • Class Antihaemorrhagics; Antihypertensives; Dihydropyridines; Esters; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Subarachnoid haemorrhage

Most Recent Events

  • 09 Apr 2025 Grace Therapeutics conducts Type C meeting with the US FDA for Subarachnoid haemorrhage
  • 10 Feb 2025 Grace Therapeutics announces intention to submit NDA to the US FDA for Subarachnoid haemorrhage in the first half of 2025
  • 10 Feb 2025 Adverse events and efficacy data from the phase-III STRIVE-ON trial in Subarachnoid haemorrhage released by Grace Therapeutics ,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top